Emergex e IBMP do Brasil Anunciam Colaboração no Desenvolvimento Clínico para Medicamentos Experimentais Relacionados ao Ponto de Regulação Imunológica do Priming de Células T
June 20, 2023 08:00 ET
|
Emergex Vaccines Holding Ltd
A Emergex e o IBMP do Brasil irão cofinanciar estudos de Fase II e Fase III da Emergex no Brasil, para medicamentos experimentais para o tratamento da Febre da Dengue e do Betacoronavírus relacionados...
Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
June 06, 2023 11:45 ET
|
Emergex Vaccines Holding Ltd
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+...
Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
November 28, 2022 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected...
Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
October 18, 2022 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox Vaccine construct comprised predominantly of peptides from early “eclipse phase” antigens...
Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma
October 12, 2022 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding...
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
July 28, 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I...
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
July 01, 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited...
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
May 17, 2022 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell...
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
April 18, 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines Both studies fully recruited, with data from the Dengue Fever...
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
April 14, 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives Emergex’s CD8+ T cell Adaptive Vaccine...